MAGEA4 and malignant colon neoplasm: Accordingly, in a patient with colon cancer treated with a MAGE-A4-associated helper/killer hybrid vaccine, Th1-dependent cellular and humoral anti-tumor responses were observed, without the occurrence of SAEs, except for a grade 2 injection site reaction.